AstraZeneca Pharma India gets CDSCO nod for expanded use of breast cancer drug Enhertu
AstraZeneca Pharma India Ltd. shares gained on Thursday, June 11, after the company received approval from India’s drug regulator for an additional indication of its cancer therapy Enhertu (trastuzumab deruxtecan), expanding its use in patients with advanced HER2-positive breast cancer. The company said it received permission from the Central Drugs Standard Control Organisation (CDSCO) on…
